| |||||||||
- Description
- Phenotype
- Genes & alleles
- Genotyping
- Health & husbandry
- References
- Purchasing information
- Terms of Use
Description
Strain Information
Former Names C57BL/6-Tg(Ins2-cre)25Mgn/J (Changed: 15-DEC-04 ) C57BL/6-TgN(Ins2-Cre)25Mgn (Changed: 15-DEC-04 ) C57BL/6-TgN(Ins2Cre)25Mgn (Changed: 15-DEC-04 ) Type Mutant Strain; Transgenic; Additional information on Genetically Engineered Mutant Mice. Mating System Homozygote x Homozygote (Female x Male) Species laboratory mouse Generation N12+1F15 (08-JAN-08) Donating Investigator Mark Magnuson, Vanderbilt University School of Medicine Description
This strain carries the "RIP-Cre" transgene construct (containing a 668 bp fragment of the rat insulin II promoter, Cre recombinase with a nuclear localization sequence, and a 2.1 kb fragment from the human growth hormone gene). Hemizygous mice carrying this transgene are phenotypically normal and overexpresss cre specifically in pancreatic beta cells. This transgene strain is used in combination with mice carrying floxed targeted mutations to create various pancreatic beta cell-specific gene knockouts using the "Cre-lox" system. Results from several different laboratories have shown that this transgenic strain is at least 85% efficient in achieving pancreatic beta cell-specific recombination. It should also be noted that the transgene in this line has been found to be expressed at a low level in the hypothalamus. In some cases this has resulted in a phenotype due to deletion of the floxed allele in this region of the brain. It has also been shown that these transgenic mice may spontaneously develop glucose intolerance and impaired insulin secretion developing at 6-8 weeks of age. It is recommended that users include naive "RIP-Cre" mice (i.e., those not bred to a floxed mutant) among the controls used in experiments.Development
A transgenic construct containing a 668 bp rat insulin II promoter, nuclear localization sequence-modified Cre recombinase and a 2.1 kb fragment from the human growth hormone gene was injected into B6D2(F2) pronuclei. The allele was subsequently moved to a C57BL/6J background.
Control Information
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying other alleles of Ins2
View Strains carrying other alleles of Ins2 (45 strains)
Additional Web Information
Congenic Nomenclature
Cre-lox Systems
Genetic Quality Control Annual Report
JAX® NOTES, Summer 2001; 482. Cre Transgenic Strains for Conditional Mutagenesis.
Phenotype
Phenotype Information
This mouse can be used to support research in many areas including:
cre relatedResearch Tools
Cre-lox System (Cre Recombinase Expression)
Diabetes and Obesity Research
Genetics Research (Mutagenesis and Transgenesis: Cre-lox System)
Research Tools
Cre-lox System
Genetics Research (Mutagenesis and Transgenesis: Cre-lox System)
Genes & Alleles
Gene & Allele Information
| Allele Symbol | Tg(Ins2-cre)25Mgn | ||
|---|---|---|---|
| Allele Name | transgene insertion 25, Mark A Magnuson | ||
| Allele Type | Transgenic (Cre/Flp) | ||
| Common Name(s) | Ins-Cre; Ins2cre; RIP Cre; RIP2-cre; Rip-cre; [RIP]-Cre; | ||
| Strain of Origin | (C57BL/6 x DBA)F2 | ||
| Site of Expression | pancreatic beta cells | ||
| Expressed Gene | cre, cre recombinase, bacteriophage P1 | ||
| Cre recombinase is an enzyme derived from the bacteriophage P1 that specifically recognizes loxP sites. Cre has been shown to effectively mediate the excision of DNA located between loxP sites. After the excision event, the DNA ends recombine leaving a single loxP site in place of the intervening sequence. | |||
| Promoter | Ins2, insulin 2, rat | ||
| Molecular Note | This transgene expresses Cre recombinase under the control of the rat insulin promoter (Ins2), which is active in pancreatic beta cells and in neurons of the hypothalmus. [MGI Ref ID J:51826] | ||
Genotyping
Genotyping Information
Genotyping Protocols
Generic Cre Melt Curve Analysis, MCA, vers. 1
Generic Cre Quantitative PCR, QPCR, vers. 1
Generic Cre, STD PCR, vers. 1
Helpful Links
Optimizing PCR Protocols
References
References
Selected Reference(s)
Postic C; Shiota M; Niswender KD; Jetton TL; Chen Y; Moates JM; Shelton KD; Lindner J; Cherrington AD; Magnuson MA. 1999. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 274(1):305-15. [PubMed: 9867845] [MGI Ref ID J:51826]
Additional References
Crabtree JS; Scacheri PC; Ward JM; McNally SR; Swain GP; Montagna C; Hager JH; Hanahan D; Edlund H; Magnuson MA; Garrett-Beal L; Burns AL; Ried T; Chandrasekharappa SC; Marx SJ; Spiegel AM; Collins FS. 2003. Of mice and MEN1: Insulinomas in a conditional mouse knockout. Mol Cell Biol 23(17):6075-85. [PubMed: 12917331] [MGI Ref ID J:85042]
Gannon M; Shiota C; Postic C; Wright CV; Magnuson M. 2000. Analysis of the Cre-mediated recombination driven by rat insulin promoter in embryonic and adult mouse pancreas. Genesis 26(2):139-42. [PubMed: 10686610] [MGI Ref ID J:69314]
Gorogawa S; Fujitani Y; Kaneto H; Hazama Y; Watada H; Miyamoto Y; Takeda K; Akira S; Magnuson MA; Yamasaki Y; Kajimoto Y; Hori M. 2004. Insulin secretory defects and impaired islet architecture in pancreatic beta-cell-specific STAT3 knockout mice. Biochem Biophys Res Commun 319(4):1159-70. [PubMed: 15194489] [MGI Ref ID J:90753]
Martin J; Hunt SL; Dubus P; Sotillo R; Nehme-Pelluard F; Magnuson MA; Parlow AF; Malumbres M; Ortega S; Barbacid M. 2003. Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number. Oncogene 22(34):5261-9. [PubMed: 12917627] [MGI Ref ID J:85130]
Rosen ED; Kulkarni RN; Sarraf P; Ozcan U; Okada T; Hsu CH; Eisenman D; Magnuson MA; Gonzalez FJ; Kahn CR; Spiegelman BM. 2003. Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol 23(20):7222-9. [PubMed: 14517292] [MGI Ref ID J:89959]
Schulla V; Renstrom E; Feil R; Feil S; Franklin I; Gjinovci A; Jing XJ; Laux D; Lundquist I; Magnuson MA; Obermuller S; Olofsson CS; Salehi A; Wendt A; Klugbauer N; Wollheim CB; Rorsman P; Hofmann F. 2003. Impaired insulin secretion and glucose tolerance in beta cell-selective Ca(v)1.2 Ca2+ channel null mice. EMBO J 22(15):3844-54. [PubMed: 12881419] [MGI Ref ID J:84919]
Tg(Ins2-cre)25Mgn relatedApostolou I; Hao Z; Rajewsky K; von Boehmer H. 2003. Effective destruction of Fas-deficient insulin-producing beta cells in type 1 diabetes. J Exp Med 198(7):1103-6. [PubMed: 14530378] [MGI Ref ID J:85985]
Atouf F; Park CH; Pechhold K; Ta M; Choi Y; Lumelsky NL. 2007. No evidence for mouse pancreatic beta-cell epithelial-mesenchymal transition in vitro. Diabetes 56(3):699-702. [PubMed: 17327438] [MGI Ref ID J:122025]
Bardoux P; Zhang P; Flamez D; Perilhou A; Lavin TA; Tanti JF; Hellemans K; Gomas E; Godard C; Andreelli F; Buccheri MA; Kahn A; Le Marchand-Brustel Y; Burcelin R; Schuit F; Vasseur-Cognet M. 2005. Essential Role of Chicken Ovalbumin Upstream Promoter-Transcription Factor II in Insulin Secretion and Insulin Sensitivity Revealed by Conditional Gene Knockout. Diabetes 54(5):1357-1363. [PubMed: 15855320] [MGI Ref ID J:98195]
Biondi CA; Gartside MG; Waring P; Loffler KA; Stark MS; Magnuson MA; Kay GF; Hayward NK. 2004. Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Mol Cell Biol 24(8):3125-31. [PubMed: 15060136] [MGI Ref ID J:89898]
Brissova M; Shostak A; Shiota M; Wiebe PO; Poffenberger G; Kantz J; Chen Z; Carr C; Jerome WG; Chen J; Baldwin HS; Nicholson W; Bader DM; Jetton T; Gannon M; Powers AC. 2006. Pancreatic islet production of vascular endothelial growth factor--a is essential for islet vascularization, revascularization, and function. Diabetes 55(11):2974-85. [PubMed: 17065333] [MGI Ref ID J:116552]
Brunham LR; Kruit JK; Pape TD; Timmins JM; Reuwer AQ; Vasanji Z; Marsh BJ; Rodrigues B; Johnson JD; Parks JS; Verchere CB; Hayden MR. 2007. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 13(3):340-7. [PubMed: 17322896] [MGI Ref ID J:121696]
Casanovas O; Hager JH; Chun MG; Hanahan D. 2005. Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis. Oncogene 24(44):6597-604. [PubMed: 16007165] [MGI Ref ID J:101759]
Chakravarthy MV; Zhu Y; Lopez M; Yin L; Wozniak DF; Coleman T; Hu Z; Wolfgang M; Vidal-Puig A; Lane MD; Semenkovich CF. 2007. Brain fatty acid synthase activates PPARalpha to maintain energy homeostasis. J Clin Invest 117(9):2539-52. [PubMed: 17694178] [MGI Ref ID J:127482]
Chase LG; Ulloa-Montoya F; Kidder BL; Verfaillie CM. 2007. Islet-derived fibroblast-like cells are not derived via epithelial-mesenchymal transition from Pdx-1 or insulin-positive cells. Diabetes 56(1):3-7. [PubMed: 17110468] [MGI Ref ID J:121938]
Choudhury AI; Heffron H; Smith MA; Al-Qassab H; Xu AW; Selman C; Simmgen M; Clements M; Claret M; Maccoll G; Bedford DC; Hisadome K; Diakonov I; Moosajee V; Bell JD; Speakman JR; Batterham RL; Barsh GS; Ashford ML; Withers DJ. 2005. The role of insulin receptor substrate 2 in hypothalamic and beta cell function. J Clin Invest 115(4):940-950. [PubMed: 15841180] [MGI Ref ID J:97406]
Covey SD; Wideman RD; McDonald C; Unniappan S; Huynh F; Asadi A; Speck M; Webber T; Chua SC; Kieffer TJ. 2006. The pancreatic beta cell is a key site for mediating the effects of leptin on glucose homeostasis. Cell Metab 4(4):291-302. [PubMed: 17011502] [MGI Ref ID J:129737]
Crabtree JS; Scacheri PC; Ward JM; McNally SR; Swain GP; Montagna C; Hager JH; Hanahan D; Edlund H; Magnuson MA; Garrett-Beal L; Burns AL; Ried T; Chandrasekharappa SC; Marx SJ; Spiegel AM; Collins FS. 2003. Of mice and MEN1: Insulinomas in a conditional mouse knockout. Mol Cell Biol 23(17):6075-85. [PubMed: 12917331] [MGI Ref ID J:85042]
Cui Y; Huang L; Elefteriou F; Yang G; Shelton JM; Giles JE; Oz OK; Pourbahrami T; Lu CY; Richardson JA; Karsenty G; Li C. 2004. Essential role of STAT3 in body weight and glucose homeostasis. Mol Cell Biol 24(1):258-69. [PubMed: 14673160] [MGI Ref ID J:87596]
Dai C; Huh CG; Thorgeirsson SS; Liu Y. 2005. {beta}-Cell-Specific Ablation of the Hepatocyte Growth Factor Receptor Results in Reduced Islet Size, Impaired Insulin Secretion, and Glucose Intolerance. Am J Pathol 167(2):429-36. [PubMed: 16049329] [MGI Ref ID J:99948]
Gannon M; Ables ET; Crawford L; Lowe D; Offield MF; Magnuson MA; Wright CV. 2008. pdx-1 function is specifically required in embryonic beta cells to generate appropriate numbers of endocrine cell types and maintain glucose homeostasis. Dev Biol 314(2):406-17. [PubMed: 18155690] [MGI Ref ID J:130389]
Gannon M; Shiota C; Postic C; Wright CV; Magnuson M. 2000. Analysis of the Cre-mediated recombination driven by rat insulin promoter in embryonic and adult mouse pancreas. Genesis 26(2):139-42. [PubMed: 10686610] [MGI Ref ID J:69314]
Gautam D; Han SJ; Hamdan FF; Jeon J; Li B; Li JH; Cui Y; Mears D; Lu H; Deng C; Heard T; Wess J. 2006. A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab 3(6):449-61. [PubMed: 16753580] [MGI Ref ID J:129643]
Gorogawa S; Fujitani Y; Kaneto H; Hazama Y; Watada H; Miyamoto Y; Takeda K; Akira S; Magnuson MA; Yamasaki Y; Kajimoto Y; Hori M. 2004. Insulin secretory defects and impaired islet architecture in pancreatic beta-cell-specific STAT3 knockout mice. Biochem Biophys Res Commun 319(4):1159-70. [PubMed: 15194489] [MGI Ref ID J:90753]
Gupta RK; Gao N; Gorski RK; White P; Hardy OT; Rafiq K; Brestelli JE; Chen G; Stoeckert CJ Jr; Kaestner KH. 2007. Expansion of adult beta-cell mass in response to increased metabolic demand is dependent on HNF-4alpha. Genes Dev 21(7):756-69. [PubMed: 17403778] [MGI Ref ID J:120377]
Gupta RK; Vatamaniuk MZ; Lee CS; Flaschen RC; Fulmer JT; Matschinsky FM; Duncan SA; Kaestner KH. 2005. The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion. J Clin Invest 115(4):1006-1015. [PubMed: 15761495] [MGI Ref ID J:97364]
Hashimoto N; Kido Y; Uchida T; Matsuda T; Suzuki K; Inoue H; Matsumoto M; Ogawa W; Maeda S; Fujihara H; Ueta Y; Uchiyama Y; Akimoto K; Ohno S; Noda T; Kasuga M. 2005. PKClambda regulates glucose-induced insulin secretion through modulation of gene expression in pancreatic beta cells. J Clin Invest 115(1):138-45. [PubMed: 15630453] [MGI Ref ID J:95378]
Inoue M; Hager JH; Ferrara N; Gerber HP; Hanahan D. 2002. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1(2):193-202. [PubMed: 12086877] [MGI Ref ID J:77131]
Kubota N; Terauchi Y; Tobe K; Yano W; Suzuki R; Ueki K; Takamoto I; Satoh H; Maki T; Kubota T; Moroi M; Okada-Iwabu M; Ezaki O; Nagai R; Ueta Y; Kadowaki T; Noda T. 2004. Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest 114(7):917-27. [PubMed: 15467830] [MGI Ref ID J:93416]
Kulkarni RN; Bruning JC; Winnay JN; Postic C; Magnuson MA; Kahn CR. 1999. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96(3):329-39. [PubMed: 10025399] [MGI Ref ID J:67938]
Kulkarni RN; Holzenberger M; Shih DQ; Ozcan U; Stoffel M; Magnuson MA; Kahn CR. 2002. beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass. Nat Genet 31(1):111-5. [PubMed: 11923875] [MGI Ref ID J:76208]
Lantz KA; Vatamaniuk MZ; Brestelli JE; Friedman JR; Matschinsky FM; Kaestner KH. 2004. Foxa2 regulates multiple pathways of insulin secretion. J Clin Invest 114(4):512-20. [PubMed: 15314688] [MGI Ref ID J:91995]
Lee CS; Sund NJ; Vatamaniuk MZ; Matschinsky FM; Stoffers DA; Kaestner KH. 2002. Foxa2 controls Pdx1 gene expression in pancreatic beta-cells in vivo. Diabetes 51(8):2546-51. [PubMed: 12145169] [MGI Ref ID J:78086]
Lee JY; Gavrilova O; Davani B; Na R; Robinson GW; Hennighausen L. 2007. The transcription factors Stat5a/b are not required for islet development but modulate pancreatic beta-cell physiology upon aging. Biochim Biophys Acta 1773(9):1455-61. [PubMed: 17599554] [MGI Ref ID J:127051]
Lee JY; Ristow M; Lin X; White MF; Magnuson MA; Hennighausen L. 2006. RIP-Cre revisited, evidence for impairments of pancreatic beta-cell function. J Biol Chem 281(5):2649-53. [PubMed: 16326700] [MGI Ref ID J:108244]
Liadis N; Salmena L; Kwan E; Tajmir P; Schroer SA; Radziszewska A; Li X; Sheu L; Eweida M; Xu S; Gaisano HY; Hakem R; Woo M. 2007. Distinct in vivo roles of caspase-8 in beta-cells in physiological and diabetes models. Diabetes 56(9):2302-11. [PubMed: 17563067] [MGI Ref ID J:126586]
Lin X; Taguchi A; Park S; Kushner JA; Li F; Li Y; White MF. 2004. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J Clin Invest 114(7):908-16. [PubMed: 15467829] [MGI Ref ID J:93415]
Martin J; Hunt SL; Dubus P; Sotillo R; Nehme-Pelluard F; Magnuson MA; Parlow AF; Malumbres M; Ortega S; Barbacid M. 2003. Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number. Oncogene 22(34):5261-9. [PubMed: 12917627] [MGI Ref ID J:85130]
Mauvais-Jarvis F; Virkamaki A; Michael MD; Winnay JN; Zisman A; Kulkarni RN; Kahn CR. 2000. A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes 49(12):2126-34. [PubMed: 11118016] [MGI Ref ID J:66009]
Miura A; Yamagata K; Kakei M; Hatakeyama H; Takahashi N; Fukui K; Nammo T; Yoneda K; Inoue Y; Sladek FM; Magnuson MA; Kasai H; Miyagawa J; Gonzalez FJ; Shimomura I. 2006. Hepatocyte nuclear factor-4alpha is essential for glucose-stimulated insulin secretion by pancreatic beta-cells. J Biol Chem 281(8):5246-57. [PubMed: 16377800] [MGI Ref ID J:108652]
Mori H; Shichita T; Yu Q; Yoshida R; Hashimoto M; Okamoto F; Torisu T; Nakaya M; Kobayashi T; Takaesu G; Yoshimura A. 2007. Suppression of SOCS3 expression in the pancreatic beta-cell leads to resistance to type 1 diabetes. Biochem Biophys Res Commun 359(4):952-8. [PubMed: 17562326] [MGI Ref ID J:122729]
Nguyen KT; Tajmir P; Lin CH; Liadis N; Zhu XD; Eweida M; Tolasa-Karaman G; Cai F; Wang R; Kitamura T; Belsham DD; Wheeler MB; Suzuki A; Mak TW; Woo M. 2006. Essential role of Pten in body size determination and pancreatic beta-cell homeostasis in vivo. Mol Cell Biol 26(12):4511-8. [PubMed: 16738317] [MGI Ref ID J:109610]
Okada T; Liew CW; Hu J; Hinault C; Michael MD; Krtzfeldt J; Yin C; Holzenberger M; Stoffel M; Kulkarni RN. 2007. From the Cover: Insulin receptors in beta-cells are critical for islet compensatory growth response to insulin resistance. Proc Natl Acad Sci U S A 104(21):8977-82. [PubMed: 17416680] [MGI Ref ID J:121640]
Otani K; Kulkarni RN; Baldwin AC; Krutzfeldt J; Ueki K; Stoffel M; Kahn CR; Polonsky KS. 2004. Reduced beta-cell mass and altered glucose sensing impair insulin-secretory function in betaIRKO mice. Am J Physiol Endocrinol Metab 286(1):E41-9. [PubMed: 14519599] [MGI Ref ID J:87825]
Pappan KL; Pan Z; Kwon G; Marshall CA; Coleman T; Goldberg IJ; McDaniel ML; Semenkovich CF. 2005. Pancreatic beta-cell lipoprotein lipase independently regulates islet glucose metabolism and normal insulin secretion. J Biol Chem 280(10):9023-9. [PubMed: 15637076] [MGI Ref ID J:97791]
Pomplun D; Florian S; Schulz T; Pfeiffer AF; Ristow M. 2007. Alterations of pancreatic beta-cell mass and islet number due to Ins2-controlled expression of Cre recombinase: RIP-Cre revisited; part 2. Horm Metab Res 39(5):336-40. [PubMed: 17533574] [MGI Ref ID J:127221]
Regard JB; Kataoka H; Cano DA; Camerer E; Yin L; Zheng YW; Scanlan TS; Hebrok M; Coughlin SR. 2007. Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion. J Clin Invest 117(12):4034-43. [PubMed: 17992256] [MGI Ref ID J:130781]
Ristow M; Mulder H; Pomplun D; Schulz TJ; Muller-Schmehl K; Krause A; Fex M; Puccio H; Muller J; Isken F; Spranger J; Muller-Wieland D; Magnuson MA; Mohlig M; Koenig M; Pfeiffer AF. 2003. Frataxin deficiency in pancreatic islets causes diabetes due to loss of beta cell mass. J Clin Invest 112(4):527-34. [PubMed: 12925693] [MGI Ref ID J:85821]
Roccisana J; Reddy V; Vasavada RC; Gonzalez-Pertusa JA; Magnuson MA; Garcia-Ocana A. 2005. Targeted inactivation of hepatocyte growth factor receptor c-met in beta-cells leads to defective insulin secretion and GLUT-2 downregulation without alteration of beta-cell mass. Diabetes 54(7):2090-102. [PubMed: 15983210] [MGI Ref ID J:100092]
Rosen ED; Kulkarni RN; Sarraf P; Ozcan U; Okada T; Hsu CH; Eisenman D; Magnuson MA; Gonzalez FJ; Kahn CR; Spiegelman BM. 2003. Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol 23(20):7222-9. [PubMed: 14517292] [MGI Ref ID J:89959]
Schulla V; Renstrom E; Feil R; Feil S; Franklin I; Gjinovci A; Jing XJ; Laux D; Lundquist I; Magnuson MA; Obermuller S; Olofsson CS; Salehi A; Wendt A; Klugbauer N; Wollheim CB; Rorsman P; Hofmann F. 2003. Impaired insulin secretion and glucose tolerance in beta cell-selective Ca(v)1.2 Ca2+ channel null mice. EMBO J 22(15):3844-54. [PubMed: 12881419] [MGI Ref ID J:84919]
Schumann DM; Maedler K; Franklin I; Konrad D; Storling J; Boni-Schnetzler M; Gjinovci A; Kurrer MO; Gauthier BR; Bosco D; Andres A; Berney T; Greter M; Becher B; Chervonsky AV; Halban PA; Mandrup-Poulsen T; Wollheim CB; Donath MY. 2007. The Fas pathway is involved in pancreatic beta cell secretory function. Proc Natl Acad Sci U S A 104(8):2861-6. [PubMed: 17299038] [MGI Ref ID J:125892]
Shigeyama Y; Kobayashi T; Kido Y; Hashimoto N; Asahara S; Matsuda T; Takeda A; Inoue T; Shibutani Y; Koyanagi M; Uchida T; Inoue M; Hino O; Kasuga M; Noda T. 2008. Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. Mol Cell Biol 28(9):2971-9. [PubMed: 18316403] [MGI Ref ID J:135811]
Silva JP; Kohler M; Graff C; Oldfors A; Magnuson MA; Berggren PO; Larsson NG. 2000. Impaired insulin secretion and beta-cell loss in tissue-specific knockout mice with mitochondrial diabetes Nat Genet 26(3):336-40. [PubMed: 11062475] [MGI Ref ID J:65522]
Stiles BL; Kuralwalla-Martinez C; Guo W; Gregorian C; Wang Y; Tian J; Magnuson MA; Wu H. 2006. Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes. Mol Cell Biol 26(7):2772-81. [PubMed: 16537919] [MGI Ref ID J:106937]
Sund NJ; Vatamaniuk MZ; Casey M; Ang SL; Magnuson MA; Stoffers DA; Matschinsky FM; Kaestner KH. 2001. Tissue-specific deletion of Foxa2 in pancreatic beta cells results in hyperinsulinemic hypoglycemia. Genes Dev 15(13):1706-15. [PubMed: 11445544] [MGI Ref ID J:70409]
Vasavada RC; Cozar-Castellano I; Sipula D; Stewart AF. 2007. Tissue-specific deletion of the retinoblastoma protein in the pancreatic beta-cell has limited effects on beta-cell replication, mass, and function. Diabetes 56(1):57-64. [PubMed: 17192465] [MGI Ref ID J:121935]
Wang L; Coffinier C; Thomas MK; Gresh L; Eddu G; Manor T; Levitsky LL; Yaniv M; Rhoads DB. 2004. Selective deletion of the Hnf1beta (MODY5) gene in beta-cells leads to altered gene expression and defective insulin release. Endocrinology 145(8):3941-9. [PubMed: 15142986] [MGI Ref ID J:91534]
Xie T; Chen M; Zhang QH; Ma Z; Weinstein LS. 2007. Beta cell-specific deficiency of the stimulatory G protein alpha-subunit Gsalpha leads to reduced beta cell mass and insulin-deficient diabetes. Proc Natl Acad Sci U S A 104(49):19601-6. [PubMed: 18029451] [MGI Ref ID J:128497]
Health & husbandry
Health & Colony Maintenance Information
Animal Health Reports
Room Number AX12
Colony Maintenance
Breeding & Husbandry When maintaining a live colony, these mice may be bred as homozygotes. Expected coat color from breeding is Black. Mating System Homozygote x Homozygote (Female x Male) Diet Information LabDiet® 5K52/5K67
Purchasing information
Pricing, Supply Level & Notes, Controls, General Terms & Conditions
Pricing
| Pricing for USA, Canada and Mexico shipping destinations |
|
Weeks of Age Price* Gender Genotypes Provided Individual Mouse Price $203.80 Female or Male Homozygous for Tg(Ins2-cre)25Mgn *Price(s) in US dollars ($)
Pairs /Price* Pair Genotype $407.60 Homozygous for Tg(Ins2-cre)25Mgn x Homozygous for Tg(Ins2-cre)25Mgn
Additional Supply Details
| Supply Notes |
|
|---|
| Pricing for International shipping destinations |
|
Weeks of Age Price* Gender Genotypes Provided Individual Mouse Price $265.00 Female or Male Homozygous for Tg(Ins2-cre)25Mgn *Price(s) in US dollars ($)
Pairs /Price* Pair Genotype $529.90 Homozygous for Tg(Ins2-cre)25Mgn x Homozygous for Tg(Ins2-cre)25Mgn
Additional Supply Details
| Supply Notes |
|
|---|
|
|
|
Supply Details
| Standard Supply | Repository-Live. A collection of over 1000 strains maintained as live colonies. Individual colonies are sized to meet current customer demand. Delivery for orders of 10 mice or less ranges on average from one to eight weeks; mice are generally shipped between four to six weeks of age with a maximum shipping age of ~nine weeks. Colony sizes do not generally support stringent age specifications for large volumes of mice; however custom orders and larger quantities of mice are easily arranged. Estimated ship dates for all orders provided within 48 hours of order placement. |
|---|---|
| Supply Notes |
|
Control Information
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
General Terms and Conditions
See Terms of Use
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering and Purchasing Information
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
Effective September 26, 2007: License Requirements for Strains using Cre-lox Technology only apply in Canada, see Licenses for Strains using Cre-lox Technology.
Contact information
General inquiries
Contracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice & Services Conditions of Use
“Each recipient institution, including its employees and other researchers under its control (RECIPIENT), of mice or services using mice from The Jackson Laboratory (TJL) agrees that such mice, descendants of those mice derived by inbreeding or crossbreeding, including unmodified derivatives of those mice or their descendants (“MICE”) shall not be: (i) used for any purpose other than the internal research of the RECIPIENT, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services with respect to MICE. Acceptance of MICE from TJL shall be deemed agreement by RECIPIENT to these conditions, and departure from these conditions requires The Jackson Laboratory’s prior written authorization.”No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.
No Liability
In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.
MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.
Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.